Conference Day Two

9.30 | Virtual Coffee & Networking

9:55 am Chair’s Opening Remarks

10:00 am Industry Experts Panel Discussion: Strategies & Approaches to Ensure Clinical and Commercial Success

  • Jason Bock Vice President & Head of Biologics Product Development, MD Anderson Cancer Center
  • Sylvia Lee Associate Professor, Program in Immunology, Clinical Research Division, Fred Hutch
  • Madan Jagasia Senior Vice President, Medical Affairs, Iovance

Synopsis

  • Discuss the interface between academia and industry in TIL therapeutic development
  • Outline the future potential for integrated partnerships to develop and execute TIL research and clinical trials

Cutting-Edge Genetic Engineering Approaches to Enhance TIL Function

11:00 am CRISPR/Cas9 Engineered TIL for Enhanced Anti-Tumor Function

  • Micah Benson Senior Vice President & Head of Immunobiology, KSQ Therapeutics

Synopsis

  • CRISPR/Cas9 screens identify top T cell targets enhancing the antitumor potency of engineered TIL (eTILTM) against solid tumors
  • Combination CRISPR screens (CRISPR2) determine the top T cell target combinations to further enhance the potency of eTILTM
  • KSQ-001 is a CRISPR/Cas9 engineered eTILTM

11:30 am
Speed Networking & Morning Refreshments

Synopsis

Like speed dating, but for business! Turn on your camera and randomly connect with speakers, delegates and partners of the conference so you can meet as many people as possible. Your random connection could lead to your next collaboration!

12:30 pm Gene Engineering to Improve Cell Function in the Tumor Microenvironment

Synopsis

  • Review the challenges of low transduction efficiencies of TIL cells selected from hostile tumor environments, what can be done to improve this?
  • Gene modification strategies to improve T-cell resistance, ability to migrate and infiltrate tumors, and targeting
  • Share engineering strategies to overcome the suppressive tumor microenvironment

1:00 pm Gene Engineering Strategies to Overcome TIL Exhaustion

  • Eduardo Davila Professor & Director of Immunotherapy Medical Oncology, University of Colorado Comprehensive Cancer Center

Synopsis

  • Genetic approaches to amplify tumor-reactive TIL activity
  • Unmasking TIL reactivity to additional neoantigens
  • Method for rapid TIL expansion in vitro and in vivo with reduced exhaustion

1.30 pm | Lunchtime Refreshments

Process Development to Set Up for Clinical Success

2:30 pm The Importance of Early Manufacturing Decisions for Building a Commercially-Scalable Personalised, Precision T Cell Therapy

  • Ed Samuel Senior Vice President, Technical Operations, Achilles Therapeutics

Synopsis

  • Addressing the challenges of cell therapy manufacturing by investing early in the design of a fully-closed and automated process for industrial scale-up
  • Building a scalable and automated process to support large scale expansion and a reduction in manufacturing timelines and costs
  • Strategies for designing a clonal neoantigen T cell therapy (cNeT) with specificity for multiple targets and maintaining potency and fitness

3:00 pm Surgical Technique for Optimal TIL Harvest in Advanced Solid Tumors

  • John Mullinax Assistant Member in the Sarcoma Department & Immunology Department, Moffitt Cancer Center

Synopsis

  • Review optimal target lesion identification for TIL harvest
  • Discuss intraoperative technique to ensure successful downstream processing and correlative assays
  • Discuss tissue processing approaches to increase TIL yield from nonmelanoma solid tumors

3:30 pm Chair’s Closing Remarks

3.40 pm | Close of the TIL Therapies Summit